9 years of historical data (2017–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BridgeBio Pharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.9B | $15.1B | $5.1B | $6.6B | $1.1B | $2.4B | $8.4B | $3.7B | — | — |
| Enterprise Value | $12.4B | $14.5B | $6.2B | $7.9B | $2.5B | $3.7B | $8.5B | $3.4B | — | — |
| P/E Ratio → | -17.54 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 25.79 | 30.05 | 23.01 | 706.43 | 14.47 | 34.54 | 1017.17 | 90.82 | — | — |
| P/B Ratio | — | — | — | — | — | — | 77.77 | 7.74 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 28.93 | 27.74 | 853.04 | 31.82 | 53.65 | 1034.11 | 84.12 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
BridgeBio Pharma, Inc. earns an operating margin of -113.3%. Operating margins have expanded from -6528.8% to -113.3% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.4% | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% | 93.8% | — | — |
| Operating Margin | -113.3% | -113.3% | -267.2% | -6528.8% | -659.6% | -827.1% | -5752.0% | -656.4% | — | — |
| Net Profit Margin | -145.3% | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.1% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -153.7% | -139.1% | — | — |
| ROA | -78.6% | -78.6% | -73.1% | -110.0% | -58.8% | -65.5% | -67.2% | -47.5% | -46.4% | -31.2% |
| ROIC | — | — | — | -738.8% | -135.1% | -121.1% | -157.6% | — | — | — |
| ROCE | -80.6% | -80.6% | -101.6% | -134.4% | -74.3% | -77.6% | -80.5% | -53.1% | -70.4% | -49.0% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $570M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 4.60 | 0.19 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | 1.29 | -0.57 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.72 | -10.72 | -5.97 | -7.47 | -6.37 | -12.33 | -12.94 | -30.38 | -72.11 | -3373.69 |
Net cash position: cash ($570M) exceeds total debt ($10M)
Short-term solvency ratios and asset-utilisation metrics
BridgeBio Pharma, Inc.'s current ratio of 2.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.32x to 2.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.62 | 2.62 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | 11.36 |
| Quick Ratio | 2.52 | 2.52 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | 11.36 |
| Cash Ratio | 4.02 | 4.02 | 4.41 | 3.02 | 3.89 | 6.19 | 6.35 | 9.04 | 13.39 | 10.76 |
| Asset Turnover | — | 0.54 | 0.24 | 0.02 | 0.12 | 0.07 | 0.01 | 0.06 | — | — |
| Inventory Turnover | 1.06 | 1.06 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 101.37 | 7.77 | 68.70 | 80.28 | 103.40 | — | 25.60 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BridgeBio Pharma, Inc. returns 0.4% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.4% | 0.3% | 0.1% | 0.1% | 0.1% | 8.5% | 0.9% | 0.0% | — | — |
| Total Shareholder Yield | 0.4% | 0.3% | 0.1% | 0.1% | 0.1% | 8.5% | 0.9% | 0.0% | — | — |
| Shares Outstanding | — | $197M | $186M | $163M | $147M | $144M | $118M | $105M | $92M | $92M |
Compare BBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BBIOYou | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BBIO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonBridgeBio Pharma, Inc.'s current P/E ratio is -17.5x. This places it at the 50th percentile of its historical range.
Based on historical data, BridgeBio Pharma, Inc. is trading at a P/E of -17.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BridgeBio Pharma, Inc. has 94.4% gross margin and -113.3% operating margin.